Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Core Insights - Mainz Biomed N.V. has appointed Petra Smeltzer Starke as a Brand Ambassador to enhance messaging on the importance of early detection of colorectal cancer [1][2] - The company plans to launch a pivotal PMA trial for its next-generation colorectal cancer screening product by the end of 2025 [2] - Mainz Biomed's flagship product, ColoAlert®, is a non-invasive diagnostic test for colorectal cancer, currently marketed in Europe and the UAE, with an ongoing pivotal FDA clinical study for US regulatory approval [6] Company Overview - Mainz Biomed specializes in molecular genetic diagnostic solutions for life-threatening conditions, focusing on early cancer detection [6] - The company is developing PancAlert, an early-stage pancreatic cancer screening test utilizing real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples [6] Brand Ambassador Profile - Petra Smeltzer Starke has a distinguished background, having studied international business and law, and served in significant roles during the Obama Administration, including General Counsel to the White House Council of Economic Advisors [3][4][5] - Starke's extensive experience and international network are expected to contribute significantly to Mainz Biomed's mission in cancer detection [2][4]